3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
29
Pain, Postoperative
10
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Stomach Neoplasms
7
Prostatic Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Melanoma
5
Ovarian Neoplasms
4
Hemorrhage
4
Head and Neck Neoplasms
4
Agnosia
4
Rectal Neoplasms
3
Neurotoxicity Syndromes
3
Nasopharyngeal Carcinoma
3
Myoma
3
Multiple Endocrine Neoplasia Type 1
3
Meningioma
3
Lymphoma, Non-Hodgkin
3
Leiomyoma
3
Glioblastoma
3
Delirium
3
Colonic Neoplasms
3
Chronic Pain
3
Warts
2
Uterine Cervical Neoplasms
2
Stomatitis
2
Skin Neoplasms
2
Interventions
Imatinib Mesylate
32
regorafenib
9
Sunitinib
9
Laparoscopy
5
Dasatinib
4
Blood Specimen Collection
4
pazopanib
3
nilotinib
3
Surveys and Questionnaires
3
Surgical Procedures, Operative
3
Paclitaxel
3
Observation
3
spartalizumab
2
ripretinib
2
envafolimab
2
binimetinib
2
apatinib
2
Temozolomide
2
Neoadjuvant Therapy
2
Ipilimumab
2
Gemcitabine
2
Docetaxel
2
Cisplatin
2
Carboplatin
2
Capecitabine
2
CTLA-4 Antigen
2
Biopsy, Fine-Needle
2
Biopsy
2
5-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-morpholin-4-ylmethylphenyl)isoxazole-3-carboxylic acid ethylamide
2
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastrointestinal Stromal Tumors
×
Sodium Chloride
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled